Paul Schoen
Amgen
14 Papers
34 Citations
Paul Schoen is an academic researcher from Amgen. The author has contributed to research in topics: Multiple myeloma & Health care. The author has an hindex of 7, co-authored 14 publications.
Chat about Author
Papers
Multiple myeloma: patient outcomes in real-world practice.
Kwee Yong,Michel Delforge,Christoph Driessen,Leah Fink,Alain Flinois,Sebastian Gonzalez-McQuire,Reza Safaei,Lionel Karlin,Maria-Victoria Mateos,Marc S. Raab,Paul Schoen,Michele Cavo +11 more
TL;DR: Investigation of patient characteristics, treatment durations and outcomes, and symptom burden across the treatment pathway in Belgium, France, Germany, Italy, Spain, Switzerland and the UK provides an insight into patient outcomes and treatment decisions being made in clinical practice.
284
Understanding mortality in multiple myeloma: Findings of a European retrospective chart review
Mohamad Mohty,Michele Cavo,Leah Fink,Sebastian Gonzalez-McQuire,Henri Leleu,Maria-Victoria Mateos,Marc S. Raab,Paul Schoen,Kwee Yong +8 more
TL;DR: This study aimed to provide real‐world data on the characteristics and treatment of patients with multiple myeloma at the time of death.
28
The use of bisphosphonates in the management of bone involvement from solid tumours and haematological malignancies - a European survey.
TL;DR: The results were generally similar across the countries, although German patients were more likely to have asymptomatic bone lesions detected during routine imaging and many have their treatment stopped when they could benefit from continued treatment.
27
Evolution of multiple myeloma treatment practices in Europe from 2014 to 2016.
Marc S. Raab,Leah Fink,Paul Schoen,Sebastian Gonzalez-McQuire,Alain Flinois,Michele Cavo,Maria-Victoria Mateos,Kwee Yong +7 more
TL;DR: Raab et al. as discussed by the authors performed a follow-up study to capture current practice in 2016, and compare the findings with those from 2014, and found that patients are increasingly receiving multiple lines of therapy, leading to improved survival.
21
Healthcare resource utilization among patients with relapsed multiple myeloma in the UK, France, and Italy.
Sebastian Gonzalez-McQuire,Kwee Yong,Henri Leleu,Francesco Saverio Mennini,Alain Flinois,Carlotta Gazzola,Paul Schoen,Marco Campioni,Lucy DeCosta,Leah Fink +9 more
TL;DR: Improved treatment outcomes, and reductions in unscheduled events and concomitant medication use may, therefore, reduce the overall HRU and related costs of care in multiple myeloma.